Ovarian

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00

National Carer’s Week – Meet the caregivers of Survivors Teaching Students

During National Carers Week, ANZGOG recognises and thanks the caregivers who bravely share their very personal stories with students across Australia and New Zealand as part of the Survivors Teaching Students® (STS) program. Survivors [...]

National Carer’s Week – Meet the caregivers of Survivors Teaching Students2021-10-13T03:06:18+11:00
Go to Top